Related Experiment Video
Updated: Apr 15, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
19.1K
[Biologics therapy for systemic lupus erythematosus. Current situation]
1Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117, Berlin, Deutschland, bimba.hoyer@charite.de.
Zeitschrift Fur Rheumatologie
|April 10, 2015
Summary
New biologic therapies targeting specific immune pathways offer novel treatment options for systemic lupus erythematosus (SLE). Belimumab, an antibody against BAFF/BLyS, is approved, with other promising biologics in development for SLE.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Context:
- Systemic lupus erythematosus (SLE) is an autoimmune disease with complex immunopathogenesis.
- Advances in understanding SLE have enabled targeted immune interventions.
- Biologics represent a significant advancement in managing inflammatory conditions like SLE.
Purpose:
- To review current immune interventions using biologics for SLE.
- To discuss the role of belimumab, a BAFF/BLyS inhibitor, in SLE treatment.
- To explore emerging biologic therapies and their potential for SLE management.
Summary:
- Belimumab, a monoclonal antibody targeting BAFF/BLyS, is approved for serologically active SLE.
- Other biologics targeting various cytokines are in clinical development for SLE.
- This review covers current biologic strategies and challenges in SLE treatment.
Impact:
- Provides an overview of advanced biologic therapies for SLE.
- Highlights belimumab's significance and the potential of novel cytokine inhibitors.
- Informs clinicians and researchers about the evolving landscape of SLE treatment options.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
804
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
804
01:28Drug Products: Biologics, Biosimilars and Interchangeables
360
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
360
01:29Inflammatory Bowel Disease IV: Pharmacological Management
989
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
989
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
716
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
716
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
682
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
682
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K